ICLIO promises to guide oncologists in community care practices to navigate the growing field of immuno-oncology.
Immuno-oncology, which has transformed the cancer treatment landscape, is rapidly being adopted into clinical practice and yielding promising results in oncology. However, questions about indications, biomarkers, cost of care, adverse effects, and reimbursement, remain. To help guide oncologists in community care practices to navigate this growing field, The Association of Community Cancer Centers has launched the Institute for Clinical Immuno-Oncology (ICLIO). Lee S. Schwartzberg, MD, FACP, chair of ICLIO had introduced ICLIO to our managed care readers through an article in Evidence-Based Oncology back in February.
ICLIO is open to all ACCC members, which includes more than 2000 cancer programs and 20,000 providers nationwide. ACCC estimates that nearly 60% of all cancer patients in the United States are treated by someone in the ACCC network.
Read the press release: http://prn.to/1dKhTgN
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen